Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Arcturus Therapeutics Ltd (ARCT)

Arcturus Therapeutics Ltd (ARCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 393,856
  • Shares Outstanding, K 26,576
  • Annual Sales, $ 12,360 K
  • Annual Income, $ -203,670 K
  • 60-Month Beta 2.74
  • Price/Sales 29.96
  • Price/Cash Flow N/A
  • Price/Book 2.16
Trade ARCT with:

Options Overview Details

View History
  • Implied Volatility 120.32% ( -2.16%)
  • Historical Volatility 81.27%
  • IV Percentile 39%
  • IV Rank 45.25%
  • IV High 160.80% on 08/01/22
  • IV Low 86.87% on 10/01/21
  • Put/Call Vol Ratio 0.41
  • Today's Volume 86
  • Volume Avg (30-Day) 404
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 8,317
  • Open Int (30-Day) 11,938

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -1.94
  • Number of Estimates 4
  • High Estimate -1.73
  • Low Estimate -2.21
  • Prior Year -2.05
  • Growth Rate Est. (year over year) +5.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.02 +13.82%
on 09/26/22
16.68 -11.15%
on 09/15/22
+0.74 (+5.26%)
since 08/30/22
3-Month
13.02 +13.82%
on 09/26/22
23.00 -35.57%
on 08/08/22
-0.92 (-5.84%)
since 06/30/22
52-Week
11.70 +26.67%
on 06/16/22
48.75 -69.60%
on 12/20/21
-32.96 (-68.98%)
since 09/30/21

Most Recent Stories

More News
Arcturus Therapeutics to Attend the Following Investor Conferences

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and...

ARCT : 14.82 (+6.01%)
Arcturus Therapeutics to Attend the Following Investor Conferences

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and...

ARCT : 14.82 (+6.01%)
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 14.82 (+6.01%)
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development...

ARCT : 14.82 (+6.01%)
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 55.43% and 714.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ARCT : 14.82 (+6.01%)
MXCT : 6.50 (+3.50%)
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development...

ARCT : 14.82 (+6.01%)
Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DTIL : 1.3000 (-0.76%)
ARCT : 14.82 (+6.01%)
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 14.82 (+6.01%)
Zealand Pharma AS (ZEAL) Stock Jumps 9.1%: Will It Continue to Soar?

Zealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down...

ZEAL : 17.59 (+1.21%)
ARCT : 14.82 (+6.01%)
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 14.82 (+6.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as...

See More

Key Turning Points

3rd Resistance Point 17.22
2nd Resistance Point 16.40
1st Resistance Point 15.61
Last Price 14.82
1st Support Level 14.00
2nd Support Level 13.18
3rd Support Level 12.39

See More

52-Week High 48.75
Fibonacci 61.8% 34.60
Fibonacci 50% 30.23
Fibonacci 38.2% 25.85
Last Price 14.82
52-Week Low 11.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar